Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Jorgensen

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Experimental Hematology & Oncology|October 17, 2018
Early detection of transformation to BPDCN in a patient with MDSKamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, et al.
Blood|April 8, 2014
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLPaolo Strati, Michael J Keating, Susan M O'Brien, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>-4</sup> and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Leukemia & Lymphoma|May 15, 2024
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaJennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, et al.
Blood|October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remissionElias Jabbour, Fadi G Haddad, Nicholas J Short, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Experimental Hematology & Oncology|October 17, 2018
Early detection of transformation to BPDCN in a patient with MDSKamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, et al.
Blood|April 8, 2014
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLPaolo Strati, Michael J Keating, Susan M O'Brien, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>-4</sup> and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Leukemia & Lymphoma|May 15, 2024
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaJennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, et al.
Blood|October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remissionElias Jabbour, Fadi G Haddad, Nicholas J Short, et al.
Pageof 5